Also known as: RSV disease
A real-world study in Galicia showed nirsevimab reduced RSV-related hospitalizations by 85.9% in the first season and 55.3% in the second. The RSV prevention market is expanding to cover high-risk children, with Beyfortus the only antibody approved for second-season use. The FDA has cited Sanofi for misleading promotional claims about the product.
Merck announced positive second RSV season findings from the Phase 3 SMART trial evaluating ENFLONSIA (clesrovimab) in infants and children under 2 years at increased risk for severe RSV disease, showing consistent safety and antibody levels similar to healthy infants.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06817889 |
Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals |
RECRUITING | PHASE2 |
